NovaBay Pharmaceuticals Receives 2nd Major NeutroPhase Order For 150,000 Units From China Pioneer Pharma

NovaBay® Pharmaceuticals, Inc. (NYSE MKT:

), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of branded pharmaceutical products and medical devices in China, has ordered an additional 150,000 units of NovaBay's NeutroPhase® Skin and Wound Cleanser. The order will enable Pioneer to launch the product in early 2015 throughout mainland China. “China will be a significant market for NeutroPhase, because the product can bring a major improvement in medical care to China and in the quality of patients' lives,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. The order follows the clearance in August of NeutroPhase for sale in China by China's Food and Drug Administration. “We're anticipating a large demand for NeutroPhase in China, because the product will help Chinese doctors address major unmet medical needs,” explained Paul Li, Chairman, Executive Director and Chief Executive Officer of Pioneer Pharma. China is now experiencing what experts call a ‘catastrophic' epidemic of diabetes. According to estimates provided by the International Diabetes Federation and the American Medical Association, 100 million Chinese already suffer from this condition and from the side effects of diabetes, such as diabetic ulcers and other chronic wounds. NovaBay's FDA-cleared NeutroPhase has shown remarkable properties in the management of these wounds. As cited in a paper published in the peer-reviewed International Journal of Burns and Trauma, “Patients showed a profound improvement after treatment with NeutroPhase® wound cleanser with and without NPWT (negative pressure wound therapy). Lab testing has shown NeutroPhase® was non-toxic to living and clinically we see no negative effects.” NeutroPhase has also been used successfully as part of a new treatment regimen to save the lives and limbs of victims of life-threatening flesh-eating disease, as Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, Calif. and NovaBay researchers reported in the journal WOUNDS. China has the highest number of reported cases of necrotizing fasciitis, or ‘flesh-eating' disease of any nation in the world. NeutroPhase contains a substance produced naturally by the immune system as a first defense against microbial invaders. Laboratory tests show that NeutroPhase not only kills bacteria that infect wounds and cause necrotizing fasciitis, it also neutralizes toxins produced by both bacteria and the immune system that impede healing and destroy healthy tissue. Those properties seen in laboratory testing enable NeutroPhase to be used effectively as the wound cleansing agent to address acute infections and aid in the management of wound care.